These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37520683)

  • 1. Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice.
    Yamazaki K; Kubara K; Ishii S; Kondo K; Suzuki Y; Miyazaki T; Mitsuhashi K; Ito M; Tsukahara K
    Mol Ther Nucleic Acids; 2023 Sep; 33():210-226. PubMed ID: 37520683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency.
    Imoto K; Tanaka M; Goya T; Aoyagi T; Takahashi M; Kurokawa M; Tashiro S; Kato M; Kohjima M; Ogawa Y
    BMC Gastroenterol; 2022 Mar; 22(1):144. PubMed ID: 35346058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency.
    Zimmer KP; Bendiks M; Mori M; Kominami E; Robinson MB; Ye X; Wilson JM
    Mol Med; 1999 Apr; 5(4):244-53. PubMed ID: 10448647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency.
    Prieve MG; Harvie P; Monahan SD; Roy D; Li AG; Blevins TL; Paschal AE; Waldheim M; Bell EC; Galperin A; Ella-Menye JR; Houston ME
    Mol Ther; 2018 Mar; 26(3):801-813. PubMed ID: 29433939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.
    Wang L; Morizono H; Lin J; Bell P; Jones D; McMenamin D; Yu H; Batshaw ML; Wilson JM
    Mol Genet Metab; 2012 Feb; 105(2):203-11. PubMed ID: 22133298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
    Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
    Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective
    Balestra D; Ferrarese M; Lombardi S; Ziliotto N; Branchini A; Petersen N; Bosma P; Pinotti M; van de Graaf SFJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228018
    [No Abstract]   [Full Text] [Related]  

  • 8. Humanized liver mouse model with transplanted human hepatocytes from patients with ornithine transcarbamylase deficiency.
    Sugahara G; Yamasaki C; Yanagi A; Furukawa S; Ogawa Y; Fukuda A; Enosawa S; Umezawa A; Ishida Y; Tateno C
    J Inherit Metab Dis; 2021 May; 44(3):618-628. PubMed ID: 33336822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector.
    De Sabbata G; Boisgerault F; Guarnaccia C; Iaconcig A; Bortolussi G; Collaud F; Ronzitti G; Sola MS; Vidal P; Rouillon J; Charles S; Nicastro E; D'Antiga L; Ilyinskii P; Mingozzi F; Kishimoto TK; Muro AF
    Mol Ther Methods Clin Dev; 2021 Mar; 20():169-180. PubMed ID: 33473356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ornithine restores ureagenesis capacity and mitigates hyperammonemia in Otc(spf-ash) mice.
    Marini JC; Lee B; Garlick PJ
    J Nutr; 2006 Jul; 136(7):1834-8. PubMed ID: 16772445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive characterization of ureagenesis in the spf
    Allegri G; Deplazes S; Rimann N; Causton B; Scherer T; Leff JW; Diez-Fernandez C; Klimovskaia A; Fingerhut R; Krijt J; Kožich V; Nuoffer JM; Grisch-Chan HM; Thöny B; Häberle J
    J Inherit Metab Dis; 2019 Nov; 42(6):1064-1076. PubMed ID: 30714172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute metabolic decompensation due to influenza in a mouse model of ornithine transcarbamylase deficiency.
    McGuire PJ; Tarasenko TN; Wang T; Levy E; Zerfas PM; Moran T; Lee HS; Bequette BJ; Diaz GA
    Dis Model Mech; 2014 Feb; 7(2):205-13. PubMed ID: 24271778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable overexpression of arginase I and ornithine transcarbamylase in HepG2 cells improves its ammonia detoxification.
    Tang N; Wang Y; Wang X; Zhou L; Zhang F; Li X; Chen Y
    J Cell Biochem; 2012 Feb; 113(2):518-27. PubMed ID: 21938740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced pluripotent stem cell technology as diagnostic tool in patients with suspected ornithine transcarbamylase deficiency lacking genetic confirmation.
    Ramosaj A; Singhal P; Schaller A; Laemmle A
    Mol Genet Metab Rep; 2023 Dec; 37():101007. PubMed ID: 38053928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mouse model of mild ornithine transcarbamylase deficiency (spf-j) displays cerebral amino acid perturbations at baseline and upon systemic immune activation.
    Tarasenko TN; Rosas OR; Singh LN; Kristaponis K; Vernon H; McGuire PJ
    PLoS One; 2015; 10(2):e0116594. PubMed ID: 25647322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperammonemia in ornithine transcarbamylase-deficient recipients following living donor liver transplantation from heterozygous carrier donors.
    Rahayatri TH; Uchida H; Sasaki K; Shigeta T; Hirata Y; Kanazawa H; Mali V; Fukuda A; Sakamoto S; Kasahara M
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27891735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery.
    Cunningham SC; Kok CY; Dane AP; Carpenter K; Kizana E; Kuchel PW; Alexander IE
    Mol Ther; 2011 May; 19(5):854-9. PubMed ID: 21386824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic variants of ornithine transcarbamylase deficiency: Nation-wide study in Japan and literature review.
    Kido J; Sugawara K; Sawada T; Matsumoto S; Nakamura K
    Front Genet; 2022; 13():952467. PubMed ID: 36303552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal treatment of ornithine transcarbamylase deficiency.
    Wilnai Y; Blumenfeld YJ; Cusmano K; Hintz SR; Alcorn D; Benitz WE; Berquist WE; Bernstein JA; Castillo RO; Concepcion W; Cowan TM; Cox KL; Lyell DJ; Esquivel CO; Homeyer M; Hudgins L; Hurwitz M; Palma JP; Schelley S; Akula VP; Summar ML; Enns GM
    Mol Genet Metab; 2018 Mar; 123(3):297-300. PubMed ID: 29396029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the Roles of Catalytic Residues in Human Ornithine Transcarbamylase.
    Watson SS; Micheloni E; Ngu L; Barnsley KK; Makowski L; Beuning PJ; Ondrechen MJ
    Biochemistry; 2024 Jul; 63(14):1858-1875. PubMed ID: 38940639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.